Durable Response of Leptomeningeal Disease With Osimertinib and Pemetrexed in EGFR-Mutated Metastatic NSCLC: A Case Report

Optimal management of EGFR-mutated NSCLC with leptomeningeal (LM) disease progression through EGFR tyrosine kinase inhibitor remains unclear. We present a 39-year-old man with EGFR-mutated NSCLC and LM disease progression through osimertinib 80 mg daily, with subsequent durable radiographic and symp...

Descripción completa

Detalles Bibliográficos
Autores principales: Merkhofer, Cristina M., Baik, Christina S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474424/
https://www.ncbi.nlm.nih.gov/pubmed/34590025
http://dx.doi.org/10.1016/j.jtocrr.2021.100177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474424/
https://www.ncbi.nlm.nih.gov/pubmed/34590025
http://dx.doi.org/10.1016/j.jtocrr.2021.100177

Ejemplares similares